Share on StockTwits
 

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating restated by UBS AG in a research note issued on Thursday, AnalystRatings.NET reports. They currently have a GBX 1,650 ($27.12) price target on the stock. UBS AG’s target price points to a potential upside of 3.25% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at BNP Paribas reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday. They now have a GBX 1,600 ($26.29) price target on the stock. Separately, analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline from GBX 1,700 ($27.94) to GBX 1,620 ($26.62) in a research note to investors on Thursday. They now have a “hold” rating on the stock. Finally, analysts at Societe Generale cut their price target on shares of GlaxoSmithKline from GBX 1,960 ($32.21) to GBX 1,950 ($32.05) in a research note to investors on Monday. They now have a “buy” rating on the stock. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 1,718.82 ($28.25).

GlaxoSmithKline (LON:GSK) traded up 1.17% on Thursday, hitting GBX 1598.00. The stock had a trading volume of 9,059,549 shares. GlaxoSmithKline has a one year low of GBX 1430.00 and a one year high of GBX 1816.00. The stock has a 50-day moving average of GBX 1602. and a 200-day moving average of GBX 1618.93. The company’s market cap is £76.976 billion.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.